New Weight-Loss shot shows promise in early trial

NCT ID NCT06118021

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 study tested an investigational drug called HS-20094 in 200 overweight or obese adults. Participants received either the drug or a placebo injection over several weeks. The main goal was to see how much weight they lost and whether the drug was safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

HS-20094 injection

What this could lead to

If successful, this could point toward a new medication to help people with obesity lose weight.

What could go wrong

This is an early Phase 2 trial with only 200 participants, so results may not apply to everyone. Side effects are possible, and the drug may not prove effective enough for further development.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The Fourth Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, 150001, China

  • the Fourth Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, 100044, China